Company Profile
Protagenic Therapeutics Stock Price, News & Analysis
- Ticker:
- PTIX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.22 USD (-14.99%)
Close
Last updated: August 6, 2026
—
Market cap
Why the stock is moving
As of Aug 6, 2026, PTIX closed down 15.0% at $0.2200. No new same-company headline was identified in the current news window.
Company overview
Business overview
Protagenic Therapeutics is a biotechnology company focused on neuropsychiatric and stress-related disorders. Its story is built around the idea that peptide-based or related approaches can address difficult CNS conditions.
Geographic Base and Sector Classification
Protagenic is headquartered in the United States and listed on NASDAQ. It sits in small-cap neuroscience biotechnology.
Business Model Characteristics
The company depends on preclinical and early clinical validation, translational credibility, and capital support. Investors typically watch early data, pipeline prioritization, and whether the company can narrow its story into a viable CNS thesis.
Position Within the Biotechnology Landscape
Protagenic occupies a speculative neuroscience niche within biotech. It is a high-risk story where platform proof matters more than near-term commercial scale.
Future catalysts
Protagenic’s catalysts are neuropeptide and CNS programs, with any update that clarifies whether the company can still produce meaningful development progress. The stock needs a cleaner clinical path.
Recent news
- 01
- 02
- 03
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
Source: Protagenic Therapeutics
- 04
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
Source: Protagenic Therapeutics
- 05
Results from Phase 1 Multiple-Dose Study of PT00114
Source: Protagenic Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Protagenic Therapeutics (PTIX)?
Protagenic Therapeutics (PTIX) most recently closed at 0.22 USD, a -14.99% move versus the previous session.
What does Protagenic Therapeutics do?
Protagenic Therapeutics is a biotechnology company focused on neuropsychiatric and stress-related disorders. Its story is built around the idea that peptide-based or related approaches can address difficult CNS conditions.
On which exchange is PTIX stock listed?
Protagenic Therapeutics (PTIX) is associated with NASDAQ, United States, Biopharma.
What is Protagenic?
Protagenic’s catalysts are neuropeptide and CNS programs, with any update that clarifies whether the company can still produce meaningful development progress.
Which conditions is Protagenic Therapeutics targeting with Protagenic?
Protagenic’s catalysts are neuropeptide and CNS programs, with any update that clarifies whether the company can still produce meaningful development progress.
How does Protagenic Therapeutics describe recent progress with Protagenic?
Protagenic’s catalysts are neuropeptide and CNS programs, with any update that clarifies whether the company can still produce meaningful development progress.
What is Therapeutics?
Protagenic Therapeutics is a biotechnology company focused on neuropsychiatric and stress-related disorders.
What should investors watch for with Therapeutics?
Protagenic’s catalysts are neuropeptide and CNS programs, with any update that clarifies whether the company can still produce meaningful development progress. The stock needs a cleaner clinical path.